EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Multiplex single-tier LymeSeek test improves sensitivity during the diagnostic gray zone of early Lyme disease

Holly Ahern iD, James Kirk, Phillip Stafford iD, Nikos Tsolakos, Mara Mandelia, Elizabeth J Horn iD, Alison Rebman, John Aucott iD, Monica E Embers iD

Journal of Clinical Microbiology · 11.11.2026 · 64 (11)

DOI: 10.1128/jcm.00879-26 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 11.11.2026. Verfasst von Holly Ahern und 8 weiteren Autor:innen. Beteiligte Einrichtung: State University of New York, Adirondack, Queensbury, New York, USA. Hauptthemen laut MEDLINE: Lyme Disease, Antibodies, Bacterial, Borrelia burgdorferi. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Focus on Lyme Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lyme disease, caused by the spirochete Borrelia burgdorferi , is the most common vector-borne disease in the U.S. and a growing public health concern due to the clinically challenging nature of the disease. Prompt antibiotic treatment early in the infection results in the best patient outcomes, while delayed treatment increases the risk of developing debilitating chronic symptoms. Because standard-of-care diagnostic tests (standardized and modified two-tier tests) have low sensitivity during the first few weeks of infection, current recommendations for diagnosing early Lyme disease rely heavily on observation and recognition of erythema migrans (EM). However, a significant proportion of Lyme disease patients develop an atypical-appearing rash, or no rash is observed. To improve diagnostic accuracy, we developed LymeSeek, a microbead-based multiplex flow immunoassay performed as a single test that detects binding of IgM and IgG antibodies to a novel combination of eight B. burgdorferi antigens. Fluorescent signals from bound antibodies are translated into a disease probability and a single test result—either detected or not detected. Overall test sensitivity across all disease stages was over 90%, with no loss of specificity. The LymeSeek test performed well in blinded panels, correctly differentiating serologically positive cases from both disease and non-disease controls. The test also identified early Lyme disease cases, with and without an observed EM rash, that were negative on the current standard-of-care two-tier serological tests. The LymeSeek test has the potential to increase diagnostic accuracy and improve patient outcomes, particularly during the diagnostic gray zone of early Lyme disease. IMPORTANCE Standard and modified two-tier serological tests for Lyme disease are not sensitive enough to diagnose patients within the first few weeks of infection, when antibiotic treatment is recognized as being most effective. This report describes a single-tier multiplex immunoassay that utilizes detection of 16 diagnostic antibodies against eight Borrelia antigens and interpretation by a machine learning-developed algorithm that demonstrates sensitivity high enough to accurately diagnose over 90% of Lyme disease cases, including those in the early diagnostic gray zone period when diagnostic uncertainty is highest. Specificity is high enough to eliminate the need for a second-tier test.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lyme DiseaseAntibodies, BacterialBorrelia burgdorferiHumansSensitivity and SpecificityImmunoglobulin MImmunoglobulin GImmunoassayFemaleAntigens, BacterialSerologic TestsMaleAdultRapid Diagnostic Tests

Stichwörter der Autor:innen

LuminexLyme diseasediagnosticsmachine learningserologysingle-tier

Substanzen

Immunoglobulin MAntibodies, BacterialImmunoglobulin GAntigens, Bacterial

Autor:innen und Institutionen

  • State University of New York, Adirondack, Queensbury, New York, USA.
  • Aces Diagnostics Inc., Paradise Valley, Arizona, USA.
  • Arizona State University, School of Life Sciences, Tempe, Arizona, USA.
  • Protavio Ltd., Athens, Greece.
  • Lyme Disease Biobank, Portland, Oregon, USA.
  • Division of Rheumatology, Department of Medicine, Lyme Disease Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Holly Ahern, Phillip Stafford, Elizabeth J Horn, John Aucott, Monica E Embers

Förderung

  • NIH HHS
  • Focus on Lyme Foundation
  • National Institutes of Health

Zitieren

APA

Ahern, H., Kirk, J., Stafford, P., Tsolakos, N., Mandelia, M., Horn, E. J., Rebman, A., Aucott, J., & Embers, M. E. (2026). Multiplex single-tier LymeSeek test improves sensitivity during the diagnostic gray zone of early Lyme disease. Journal of Clinical Microbiology, 64(11). https://doi.org/10.1128/jcm.00879-26

Vancouver

Ahern H, Kirk J, Stafford P, Tsolakos N, Mandelia M, Horn EJ, et al. Multiplex single-tier LymeSeek test improves sensitivity during the diagnostic gray zone of early Lyme disease. Journal of Clinical Microbiology. 2026;64(11). doi:10.1128/jcm.00879-26

BibTeX
@article{Ahern2026,
  author = {Ahern, Holly and Kirk, James and Stafford, Phillip and Tsolakos, Nikos and Mandelia, Mara and Horn, Elizabeth J and Rebman, Alison and Aucott, John and Embers, Monica E},
  title = {Multiplex single-tier LymeSeek test improves sensitivity during the diagnostic gray zone of early Lyme disease},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  volume = {64},
  number = {11},
  doi = {10.1128/jcm.00879-26}
}
Kostenlos starten →